Aortic dilatation and gastrointestinal disease: expansion of the hyperinsulinism-polycystic kidney disease phenotype
Open Access
- 21 October 2026
- journal article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (12)
Abstract
Context: Congenital hyperinsulinism (HI) with polycystic kidney disease (PKD), or HIPKD, is a recently described syndrome caused by a specific promotor variant in PMM2, a gene otherwise associated with PMM2 congenital disorder of glycosylation. Objective: To describe the HIPKD clinical phenotype, expanding our understanding and its distinction from the congenital disorder of glycosylation phenotype. Design: Retrospective multicenter cohort study of individuals with HIPKD identified through an international HI genetic referral center. Patients: Ten individuals from 9 families compound heterozygous for the promoter variant c.-167G > T and a pathogenic intragenic variant in PMM2. Intervention: None. Main Outcome Measures: Observed clinical features and outcomes. Results: Median age of presentation was 5 months (range 0-42). Median age at follow up was 12.7 years (range 5.4-20.1). HI was managed with diazoxide monotherapy (7/10 patients), diazoxide and nifedipine (2/10 patients), and carbohydrate supplementation alone (1/10 patient). PKD age at diagnosis and severity was variable, ranging from antenatal presentation requiring renal transplantation, to incidental detection in mid-childhood. Liver cysts were noted in 6/10 patients (5/6 with normal liver function). Five of 7 patients had systemic hypertension and 3/5 were normotensive on losartan at last follow up. Inflammatory bowel disease (IBD) with gastric antral foveolar hyperplasia occurred in 4/10 patients, and aortic root and/or ascending aortic dilation in 4/7 patients who underwent echocardiography, 3 of whom also had IBD. Conclusion: HIPKD due to a PMM2 promoter variant is associated with broad, multisystem phenotype, including IBD and aortic dilation. These findings support targeted screening for IBD and cardiovascular surveillance in addition to standard endocrine and renal follow up.Keywords
This publication has 23 references indexed in Scilit:
- Clinical severity and cardiac phenotype in phosphomannomutase 2‐congenital disorders of glycosylation : Insights into genetics and management recommendationsJournal of Inherited Metabolic Disease, 2024
- Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohortMolecular Genetics and Metabolism, 2024
- Phosphomannomutase 2 (PMM2) variants leading to hyperinsulinism-polycystic kidney disease are associated with early-onset inflammatory bowel disease and gastric antral foveolar hyperplasiaHuman Genetics, 2023
- Expanding the variability of the ADPKD-GANAB clinical phenotype in a family of Italian ancestryJournal Of Nephrology, 2021
- Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)Molecular Genetics & Genomic Medicine, 2021
- Cystic kidney diseases associated with mutations in phosphomannomutase 2 promotor: a large spectrum of phenotypesPediatric Nephrology, 2021
- Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus ConferenceKidney International, 2020
- Aortic dilatation in children with mild to moderate chronic kidney diseasePediatric Nephrology, 2020
- Renal involvement in PMM2-CDG, a mini-reviewMolecular Genetics and Metabolism, 2018
- Aortic dilatation in children with systemic hypertensionJournal of the American Society of Hypertension, 2014